{"schema_version":"secwatch.filing_event.v1","accession":"0000711404-24-000016","form_type":"8-K","ticker":"COO","cik":"0000711404","company_name":"COOPER COMPANIES, INC.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.719367+00:00","generated_at":"2026-06-05T07:33:20.630499+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cooper Q1 revenue record $931.6M (+9% YoY); non-GAAP EPS $0.85 (+18%); FY24 guidance raised","bullets":["Revenue of $931.6M, up 9% YoY; CooperVision $621.5M (+7%), CooperSurgical $310.1M (+12%).","GAAP EPS $0.41 (down 5% YoY); non-GAAP EPS $0.85 (up 18% YoY).","Gross margin improved to 67% (GAAP and non-GAAP) from 65%/66% last year.","FY2024 guidance raised: revenue $3,847-$3,897M, non-GAAP EPS $3.50-$3.58.","4-for-1 stock split effective Feb 20, 2024; free cash flow $4.6M; net debt $2.6B."],"urls":{"canonical":"https://secwatch.observer/filing/0000711404-24-000016","json":"https://secwatch.observer/filing/0000711404-24-000016.json","markdown":"https://secwatch.observer/filing/0000711404-24-000016.md","text":"https://secwatch.observer/filing/0000711404-24-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/711404/000071140424000016/0000711404-24-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/711404/000071140424000016/coo-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:33:20.630499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"57d92bd4408f3b6cf450dcb98809ad01f59b8111","claim":"COOPER COMPANIES, INC. reported its fiscal first quarter ended January 31, 2024 results: revenue $931.6 million, EPS $0.41. Guidance raised.","evidence_excerpt":"COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2024. • Revenue increased 9% year-over-year to $931.6 million. CooperVision (CVI) revenue up 7% to $621.5 million, and CooperSurgical (CSI) revenue up 12% to $310.1 million. • GAAP diluted earnings per share (EPS) of $0.41, down $0.02 or 5%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/711404/000071140424000016/0000711404-24-000016-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"its fiscal first quarter ended January 31, 2024"},{"label":"Revenue","value":"$931.6 million"},{"label":"EPS","value":"$0.41"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}